The Recall Desk
HighFDA (Drugs)·D-0463-2023·Announced 2023-03-22

Clobazam Tablets Recalled Due to Cross Contamination Risk

Breckenridge Pharmaceutical is recalling Clobazam 20 mg tablets (Lot #5210147, exp. 12/2023) nationwide due to potential cross contamination from manufacturing deviations.

What this means for you

Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.

Our severity reasoning: This is an FDA Class II recall with potential cross contamination due to CGMP deviations. No illnesses or injuries have been reported, which caps the severity at High per the rubric for theoretical hazards without reported harm.

Plain-English summary

Clobazam Tablets, 20 mg (Lot #5210147, expiration 12/2023) manufactured by Centaur Pharmaceuticals Pvt. Ltd. and distributed by Breckenridge Pharmaceutical, Inc. are being recalled.

The FDA-classified Class II recall was issued due to potential cross contamination resulting from Current Good Manufacturing Practice (CGMP) deviations. No illnesses or injuries have been reported related to this product.

The affected medication was distributed nationwide. Patients currently taking this product should consult their healthcare provider or pharmacist before discontinuing use.

The recalled product

Product
Clobazam Tablets, 20 mg, CIV, 100-count bottle, Rx only, Manufactured by Centaur Pharmaceuticals Pvt. Ltd., Pune, INDIA, Distributed by: Breckenridge Pharmaceuticals, Inc., Berlin, CT 06037, NDC 51991-901-01
Manufacturer
Breckenridge Pharmaceutical, Inc
Category
Drug
Hazard
  • cross-contamination
  • manufacturing-defect

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (2)

  • Lot # 5210147
  • Exp 12/2023

Distribution

Distributed nationwide across the United States.